Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study

Key Points

• Poor survival outcomes can be predicted using inflammatory biomarkers, such as NLR and SII.
• Inflammatory biomarkers were assessed over time to evaluate their effectiveness for predicting outcomes.
• Assessment method involved the serial evaluation of biomarkers in patients with metastatic colorectal cancer.
• These findings highlight the potential of inflammatory biomarkers as a tool for improving treatment strategies.

Abstract